Food fussiness a largely genetic trait from toddlerhood to adolescence
On Sept. 20, 2024, a study led by researchers from University College London (UCL), King’s College London and…
Introducing peanut in infancy Prevents peanut allergy into adolescence
On May 28, 2024, a National Institute of Allergy and Infectious Diseases (NIAID) funded study reported that feeding…
FDA approved Xolair as first and only medicine for children and adults with one or more food allergies
On Feb. 16. 2024, Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair…
COVID-19 vaccination and boosting during pregnancy protects infants for six months
On Feb. 14, 2024, the National Institute of Allergy and Infectious Diseases (NIAID) reported study results that showed…
NIAID scientists found Infectious SARS-CoV-2 in patient blood
On Dec. 13, 2023, National Institute of Allergy and Infectious Diseases (NIAID) scientists announced findings published in the…
National Institutes of Health clinical trial of universal flu vaccine candidate began
On Sept. 15, 2023, researchers at the National Institute of Allergy and Infectious Diseases announced they had begun…
NIH investigated multidrug-resistant bacterium emerging in community settings
On Sept. 6, 2023, the National Institutes of Health (NIH) announced it was investgating ‘hypervirulent’ strains of the…
COVID-19 vaccination and boosting during pregnancy benefits pregnant women and newborns
On Aug. 11, 2023, a study funded by the National Institute of Allergy and Infectious Diseases (NIAID) reported…
NIAID Service IDs 3,000 natural products for disease-fighting potential
On Jun. 1, 2023, the National Institute of Allergy and Infectious Diseases and the National Cancer Institute reported…
NIH scientists develop mouse model to study Mpox virulence
On Feb. 14, 2023, scientists from the National Institute of Allergy and Infectious Diseases announced they had developed…
Clinical trial evaluating Mpox vaccine began
On Sept. 8, 2022, a clinical trial evaluating alternative strategies for administering the JYNNEOS mpox vaccine to increase…
Vaccine-induced immune response to Omicron wanes substantially over time
On Jul. 19, 2022, the NIH announced that although COVID-19 booster vaccinations in adults elicit high levels of…
NIH launched clinical trial of mRNA Nipah virus vaccine
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
Trial of potential universal flu vaccine opened at NIH Clinical Center
On Jun. 28, 2022, the National Institutes of Health (NIH) announced that a Phase 1 clinical trial of…
Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
NIH launched clinical trial of Epstein-Barr virus vaccine
On May 6, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had launched…
Cocrystal Pharma collaborated with the NIAID to evaluate COVID-19 protease inhibitors
On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and…
NIH funded new tuberculosis research advancement centers
On Mar. 9, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced four grant awards to…
COVID-19 | HIV | Life Science News | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
NIH launched trial to study allergic reactions to COVID-19 mRNA vaccine
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
Oral immunotherapy induced remission of peanut allergy in some young children
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
Humanigen announced target enrollment in phase 2/3 ACTIV-5/BET-B trial of Lenzilumab for treatment of COVID-19 was met
On Jan. 5, 2021, Humanigen announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study had been achieved….
NIAID issued new awards to fund ‘pan-coronavirus’ vaccines
On Sept. 28, 2021, the National Institute of Allergy and Infectious Diseases announced it had awarded approximately $36.3…
NIH launched study of extra COVID-19 vaccine dose in people with autoimmune disease
On Aug. 27, 2021, The National Institutes of Health announced that it had begun a clinical trial to…
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, a first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle…
NIH clinical trial evaluating mixed COVID-19 vaccine schedules began
On Jun. 1, 2021, the National Institutes of Health announced that it had started a Phase 1/2 clinical…
NIAID scientists found that Salmonella use intestinal epithelial cells to colonize the gut
On May 26, 2021, NIH scientists reported that the immune systemï¾’s attempt to eliminate Salmonella bacteria from the…
NIH established new childhood asthma clinical research network
On Apr. 23, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had awarded…
Large NIH clinical trial tested polyclonal antibody therapeutic for COVID-19
On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal…
IH closed enrollment in trial comparing COVID-19 treatment regimens
On Apr. 15, 2021, The National Institute of Allergy and Infectious Diseases (NIAID) announced that the fourth iteration…